These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

578 related articles for article (PubMed ID: 15347339)

  • 1. Open study of the efficacy and mechanism of action of topical imiquimod in basal cell carcinoma.
    Vidal D; Matías-Guiu X; Alomar A
    Clin Exp Dermatol; 2004 Sep; 29(5):518-25. PubMed ID: 15347339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of imiquimod for the expression of Bcl-2, Ki67, p53 and basal cell carcinoma apoptosis.
    Vidal D; Matías-Guiu X; Alomar A
    Br J Dermatol; 2004 Sep; 151(3):656-62. PubMed ID: 15377354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo characterization of the inflammatory infiltrate and apoptotic status in imiquimod-treated basal cell carcinoma.
    De Giorgi V; Salvini C; Chiarugi A; Paglierani M; Maio V; Nicoletti P; Santucci M; Carli P; Massi D
    Int J Dermatol; 2009 Mar; 48(3):312-21. PubMed ID: 19261026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of superficial basal cell carcinomas after treatment with imiquimod 5% cream or vehicle for apoptosis and lymphocyte phenotyping.
    Sullivan TP; Dearaujo T; Vincek V; Berman B
    Dermatol Surg; 2003 Dec; 29(12):1181-6. PubMed ID: 14725659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imiquimod treatment of superficial and nodular basal cell carcinoma: 12-week open-label trial.
    Peris K; Campione E; Micantonio T; Marulli GC; Fargnoli MC; Chimenti S
    Dermatol Surg; 2005 Mar; 31(3):318-23. PubMed ID: 15841634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Topical imiquimod therapy for basal and squamous cell carcinomas: a clinical experience.
    Tillman DK; Carroll MT
    Cutis; 2007 Mar; 79(3):241-8. PubMed ID: 17674590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topical imiquimod treatment for nodular basal cell carcinomas: an open-label series.
    Huber A; Huber JD; Skinner RB; Kuwahara RT; Haque R; Amonette RA
    Dermatol Surg; 2004 Mar; 30(3):429-30. PubMed ID: 15008876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens.
    Shumack S; Robinson J; Kossard S; Golitz L; Greenway H; Schroeter A; Andres K; Amies M; Owens M
    Arch Dermatol; 2002 Sep; 138(9):1165-71. PubMed ID: 12224977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of all basal cell carcinoma variants including large and high-risk lesions with 5% imiquimod cream: histological and clinical changes, outcome, and follow-up.
    Schiessl C; Wolber C; Tauber M; Offner F; Strohal R
    J Drugs Dermatol; 2007 May; 6(5):507-13. PubMed ID: 17679185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion.
    Sterry W; Ruzicka T; Herrera E; Takwale A; Bichel J; Andres K; Ding L; Thissen MR
    Br J Dermatol; 2002 Dec; 147(6):1227-36. PubMed ID: 12452875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-Term Follow-Up Results of Topical Imiquimod Treatment in Basal Cell Carcinoma.
    Bostanci S; Kocyigit P; Vural S; Heper AO; Botsali A
    Dermatol Surg; 2018 Jan; 44(1):36-41. PubMed ID: 29016542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial.
    Arits AH; Mosterd K; Essers BA; Spoorenberg E; Sommer A; De Rooij MJ; van Pelt HP; Quaedvlieg PJ; Krekels GA; van Neer PA; Rijzewijk JJ; van Geest AJ; Steijlen PM; Nelemans PJ; Kelleners-Smeets NW
    Lancet Oncol; 2013 Jun; 14(7):647-54. PubMed ID: 23683751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Topical imiquimod treatment of superficial and nodular basal cell carcinomas in patients affected by basal cell nevus syndrome: a preliminary report.
    Micali G; De Pasquale R; Caltabiano R; Impallomeni R; Lacarrubba F
    J Dermatolog Treat; 2002 Sep; 13(3):123-7. PubMed ID: 12227875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of facial superficial basal cell carcinomas with imiquimod 5% cream.
    Mirza B; De'Ambrosis B
    Clin Exp Dermatol; 2003 Nov; 28 Suppl 1():16-8. PubMed ID: 14616806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imiquimod 5% cream as adjunctive therapy for primary, solitary, nodular nasal basal cell carcinomas before Mohs micrographic surgery: a randomized, double blind, vehicle-controlled study.
    Butler DF; Parekh PK; Lenis A
    Dermatol Surg; 2009 Jan; 35(1):24-9. PubMed ID: 19018814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful treatment of multiple superficial basal cell carcinomas with topical imiquimod: case report and review of the literature.
    Drehs MM; Cook-Bolden F; Tanzi EL; Weinberg JM
    Dermatol Surg; 2002 May; 28(5):427-9. PubMed ID: 12030878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Superficial basal cell carcinoma treated with imiquimod 5% topical cream for a 4-week period: a case series.
    Ruiz-Villaverde R; Sánchez-Cano D; Burkhardt-Pérez P
    J Eur Acad Dermatol Venereol; 2009 Jul; 23(7):828-31. PubMed ID: 19646136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma: a systematic review.
    Love WE; Bernhard JD; Bordeaux JS
    Arch Dermatol; 2009 Dec; 145(12):1431-8. PubMed ID: 20026854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imiquimod 5% cream as pretreatment of Mohs micrographic surgery for nodular basal cell carcinoma in the face: a prospective randomized controlled study.
    van der Geer S; Martens J; van Roij J; Brand E; Ostertag JU; Verhaegh ME; Neumann HA; Krekels GA
    Br J Dermatol; 2012 Jul; 167(1):110-5. PubMed ID: 22385074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two-year interim results from a 5-year study evaluating clinical recurrence of superficial basal cell carcinoma after treatment with imiquimod 5% cream daily for 6 weeks.
    Quirk C; Gebauer K; Owens M; Stampone P
    Australas J Dermatol; 2006 Nov; 47(4):258-65. PubMed ID: 17034468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.